{
    "clinical_study": {
        "@rank": "68661", 
        "arm_group": [
            {
                "arm_group_label": "Part A, 1 mg/kg CNTO 136", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part A, 4 mg/kg CNTO 136", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part A, 10 mg/kg CNTO 136", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part B, 10 mg/kg CNTO 136/placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study was to evaluate the safety and pharmacokinetics (PK, the\n      action of a drug in the body over a period of time) of multiple intravenous (IV)\n      administrations of CNTO 136 in patients with cutaneous lupus erythematosus (CLE) and\n      systemic lupus erythematosus (SLE). The secondary goal of this study was to assess the\n      pharmacodynamics (biochemical and physiological effects of a drug and the mechanisms of\n      action), immune response, and  clinical response."
        }, 
        "brief_title": "A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus", 
        "completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Lupus Erythematosus, Cutaneous", 
            "Lupus Erythematosus, Systemic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lupus Erythematosus, Cutaneous", 
                "Lupus Erythematosus, Systemic"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Part A of this study, patients with CLE were randomly assigned (like flipping a coin) to\n      receive multiple IV doses of CNTO 136, a human anti-IL 6 monoclonal antibody (an immune\n      protein that binds to interleukin 6) or placebo (a substance that appears identical to the\n      treatment and has no active ingredients). Patients and study personnel did not know the\n      identity of the administered treatments (double-blind study). Increasing doses were given,\n      based on safety data collected during the initial weeks of treatment. In Part B, which was\n      also double-blind, patients with SLE were randomly assigned to receive multiple IV doses of\n      the highest well-tolerated dose, as determined in Part A, of CNTO 136, or placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of cutaneous lupus erythematosus (CLE, including subacute cutaneous lupus\n             erythematosus, discoid lupus erythematosus, or lupus erythematosus tumidus) or\n             systemic lupus erythematosus (SLE)\n\n               -  Had a body weight less than or equal to 100 kg\n\n               -  Patients in Part A who were taking systemic medications for CLE had to be on a\n                  stable dose for 4 weeks before the first study agent infusion\n\n               -  Patients in Part B taking systemic medications for SLE had to be on a stable\n                  dose for at least 3 months before the first study agent infusion\n\n               -  Given informed consent and willing and able to adhere to the study visit\n                  schedule and other protocol requirements; agreed to avoid alcohol intake; and\n                  took adequate measures to prevent pregnancy\n\n        Exclusion Criteria:\n\n          -  Significant history of or concurrent medical condition (other than lupus)\n\n          -  Use of specific previous or concurrent medications or investigational therapies\n\n          -  Known or suspected allergy to the study agent or it constituents, having recently\n             donated blood, or having any significant laboratory test values requiring\n             intervention\n\n          -  Patients with SLE in Part B could not have active central nervous system lupus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702740", 
            "org_study_id": "CR013000", 
            "secondary_id": [
                "C0136T03", 
                "2006-002432-25"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A, 1 mg/kg CNTO 136", 
                "description": "Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.", 
                "intervention_name": "1 mg/kg CNTO 136", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part A, 4 mg/kg CNTO 136", 
                "description": "Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.", 
                "intervention_name": "4 mg/kg CNTO 136", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A, 10 mg/kg CNTO 136", 
                    "Part B, 10 mg/kg CNTO 136/placebo"
                ], 
                "description": "Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.", 
                "intervention_name": "10 mg/kg CNTO 136", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B, 10 mg/kg CNTO 136/placebo", 
                "description": "Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cutaneous lupus erythematosus", 
            "Systemic lupus erythematosus", 
            "Lupus erythematosus", 
            "Human anti-IL 6 monoclonal antibody", 
            "Sirukumab"
        ], 
        "lastchanged_date": "October 5, 2012", 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus", 
        "overall_official": {
            "affiliation": "Centocor Research & Development, Inc.", 
            "last_name": "Centocor Research & Development, Inc., PA, USA Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "description": "Blood serum concentration over time", 
                "measure": "Pharmacokinetic profile of CNTO 136", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "description": "Assessment of head, eyes, ears, nose and throat, skin and neck, lungs, heart, abdomen, extremities, general neurologic status, and oral examination", 
                "measure": "Physical examinations", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Electrocardiograms (ECGs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Sitting blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Respiration rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Oral temperature", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Hemoglobin", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Hematocrit", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Platelets and total white blood cells (WBC)", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Albumin and total protein", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Blood urea nitrogen (BUN), calcium, creatinine, and total bilirubin", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Chloride, potassium, and sodium", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Bicarbonate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Creatine kinase", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Gamma-glutamyl-transferase", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Glucose", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Lymphocytes and neutrophils", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Inorganic phosphate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "description": "Total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL), and triglycerides.", 
                "measure": "Fasting Lipid Panel", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702740"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage change from baseline in serum and plasma biomarker data", 
                "measure": "Pharmacodynamics evaluations", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "description": "The formation of antibodies to CNTO 136", 
                "measure": "Immune response", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "description": "Measurement of disease activity, scored from 0 (absent) to 70 (severe), and damage, scored from 0 (absent) to 56 (severe)", 
                "measure": "Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "description": "Measures the need for alterations or intensification of therapy. The assessing physician considers each item as to its presence in the past month, and answers 0 = not present, 1 = improving; 2 = same; 3 = worse; or 4 = new.", 
                "measure": "British Isles Lupus Assessment Group (BILAG) score", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "description": "Assesses the presence and severity of lupus flare. Scores range from 0 (mild)  to 105 (severe).", 
                "measure": "SELENA-SLEDAI Flare Composite", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }
        ], 
        "source": "Centocor Research & Development, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centocor Research & Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}